# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS3/24 - Analyty krevního séra

Stop termín: 26.7.2024

Nastavení: skupiny - R (výrobce reagencií); minimální četnost skupin n = 5

| | | |
|---|---|---|
| RoM = robustní průměr | AV = vztažná hodnota | $D_{max}$ = přijatelný rozdíl |
| SD = směrodatná odchylka | CRV = certifikovaná referenční hodnota | LL = dolní mez |
| CV = variační koeficient | CVP = konsenzus všech účastníků | UL = horní mez |
| $N_{tot}$ = celkový počet výsledků | CVPG = konsenzus skupin účastníků | $N_{eva}$ = počet hodnocených výsledků |
| $N_{out}$ = počet výsledků vyloučených před výpočtem | $U_{AV}$ = rozšířená nejistota vztažné hodnoty (k = 2) | $N_{suc}$ = počet úspěšných výsledků |
| | | $S_{rel}$ = relativní úspěšnost |

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost | | | | | | | | | Návaznost | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
| (22) **α-amyláza** | [µkat/L] | | | | 150 | | | | | | | | 0 | | | | | | | | | 148 | 144 | 97 |
| **Vzorek A** | | 5,93 | 0,42 | 7 | 150 | | | | | | | | 0 | | | | | | | | | 148 | 146 | 99 |
| (1) Abbott | | 6,28 | 0,13 | 2,1 | 30 | 0 | | | | | | | | | | CRV | 5,98 | 0,16 | 15% | 5,08 | 6,88 | 30 | | |
| (46) Erba Lachema | | 6,07 | 0,11 | 1,8 | 9 | 0 | | | | | | | | | | CRV | 5,98 | 0,16 | 15% | 5,08 | 6,88 | 9 | | |
| (58) Beckman Coulter (AU) | | 6,01 | 0,22 | 3,6 | 22 | 0 | | | | | | | | | | CRV | 5,98 | 0,16 | 15% | 5,08 | 6,88 | 22 | | |
| (60) Roche | | 5,57 | 0,1 | 1,9 | 62 | 0 | | | | | | | | | | CRV | 5,98 | 0,16 | 15% | 5,08 | 6,88 | 62 | | |
| (162) Siemens (Atellica) | | 6,39 | 0,096 | 1,5 | 15 | 0 | | | | | | | | | | CRV | 5,98 | 0,16 | 15% | 5,08 | 6,88 | 15 | | |
| Ostatní | | | | | 12 | 0 | | | | | | | 0 | | | | | | | | | 10 | | |
| | | | | | | | 2x 149 | | | | | | | | | 1x 12, 1x 49, 1x 85, 2x 149, 4x 177, 3x 179 | | | | | | | | |
| **Vzorek B** | | 4,85 | 0,36 | 7,4 | 150 | | | | | | | | 0 | | | | | | | | | 148 | 144 | 97 |
| (1) Abbott | | 5,19 | 0,11 | 2,2 | 30 | 0 | | | | | | | | | | CRV | 4,72 | 0,14 | 15% | 4,01 | 5,43 | 30 | | |
| (46) Erba Lachema | | 4,95 | 0,16 | 3,1 | 9 | 0 | | | | | | | | | | CRV | 4,72 | 0,14 | 15% | 4,01 | 5,43 | 9 | | |
| (58) Beckman Coulter (AU) | | 4,88 | 0,15 | 3 | 22 | 0 | | | | | | | | | | CRV | 4,72 | 0,14 | 15% | 4,01 | 5,43 | 22 | | |
| (60) Roche | | 4,53 | 0,081 | 1,8 | 62 | 0 | | | | | | | | | | CRV | 4,72 | 0,14 | 15% | 4,01 | 5,43 | 62 | | |
| (162) Siemens (Atellica) | | 5,23 | 0,083 | 1,6 | 15 | 0 | | | | | | | | | | CRV | 4,72 | 0,14 | 15% | 4,01 | 5,43 | 15 | | |
| Ostatní | | | | | 12 | 0 | | | | | | | 0 | | | | | | | | | 10 | | |
| | | | | | | | 2x 149 | | | | | | | | | 1x 12, 1x 49, 1x 85, 2x 149, 4x 177, 3x 179 | | | | | | | | |
| (35) **α-amyláza pankreatická** | [µkat/L] | | | | 67 | | | | | | | | 67 | 66 | 99 | | | | | | | 0 | | |
| **Vzorek A** | | 5,01 | 0,25 | 5 | 67 | | CVP | 5,01 | 0,074 | 18% | 4,1 | 5,92 | 67 | 66 | 99 | | | | | | | 0 | | |
| (1) Abbott | | 4,87 | 0,2 | 4,1 | 15 | 0 | | | | | | | 15 | | | | | | | | | | | |
| (46) Erba Lachema | | 5,25 | 0,27 | 5,1 | 8 | 0 | | | | | | | 8 | | | | | | | | | | | |
| (60) Roche | | 4,91 | 0,14 | 2,8 | 27 | 0 | | | | | | | 27 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 5,66 | 0,052 | 0,92 | 7 | 0 | | | | | | | 7 | | | | | | | | | | | |
| Ostatní | | | | | 10 | 0 | | | | | | | 10 | | | | | | | | | | | |
| | | | | | | | 3x 58, 4x 116, 1x 178, 2x 179 | | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 4,13 | 0,18 | 4,3 | 67 | | CVP | 4,13 | 0,053 | 18% | 3,38 | 4,88 | 67 | 66 | 99 | | | | | | | 0 | | |
| (1) Abbott | | 4,03 | 0,16 | 4,1 | 15 | 0 | | | | | | | 15 | | | | | | | | | | | |
| (46) Erba Lachema | | 4,32 | 0,22 | 5 | 8 | 0 | | | | | | | 8 | | | | | | | | | | | |
| (60) Roche | | 4,06 | 0,11 | 2,6 | 27 | 0 | | | | | | | 27 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 4,69 | 0,045 | 0,95 | 7 | 0 | | | | | | | 7 | | | | | | | | | | | |
| Ostatní | | | | | 10 | 0 | | | | | | | 10 | | | | | | | | | | | |
| | | | | | | | 3x 58, 4x 116, 1x 178, 2x 179 | | | | | | | | | | | | | | | | | |
| (32) **γ-globulin (elfo)** | [-] | | | | 35 | | | | | | | | 35 | 35 | 100 | | | | | | | 0 | | |
| **Vzorek A** | | 0,127 | 0,014 | 11 | 35 | | CVP | 0,127 | 0,006 | 30% | 0,088 | 0,166 | 35 | 35 | 100 | | | | | | | 0 | | |
| (34) Sebia | | 0,124 | 0,013 | 10 | 29 | 0 | | | | | | | 29 | | | | | | | | | | | |
| (213) Interlab Srl | | 0,139 | 0,013 | 9,1 | 5 | 0 | | | | | | | 5 | | | | | | | | | | | |
| Ostatní | | | | | 1 | 0 | | | | | | | 1 | | | | | | | | | | | |
| | | | | | | | 1x 0 | | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 0,123 | 0,012 | 9,8 | 35 | | CVP | 0,123 | 0,005 | 30% | 0,086 | 0,16 | 35 | 35 | 100 | | | | | | | 0 | | |
| (34) Sebia | | 0,123 | 0,012 | 10 | 29 | 0 | | | | | | | 29 | | | | | | | | | | | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS3/24 - Analyty krevního séra

Stop termín: 26.7.2024

Nastavení: skupiny - R (výrobce reagencií); minimální četnost skupin n = 5

| Zkouška<br>Vzorek<br>Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost | | | | | | | | | Návaznost | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
| (213) Interlab Srl | | 0,119 | 0,004 | 3,7 | 5 | 0 | | | | | | | 5 | | | | | | | | | | | |
| Ostatní | | | | | 1 | 0 | | | | | | | 1 | | | | | | | | | | | |
| | | | | | | | 1x 0 | | | | | | | | | | | | | | | | | |
| (10) **Albumin** | [g/L] | | | | 145 | | | | | | | | 145 | 140 | 97 | | | | | | | 0 | | |
| **Vzorek A** | | 44,4 | 1,4 | 3,1 | 145 | | CVP | 44,4 | 0,28 | 10% | 39,9 | 48,9 | 145 | 144 | 99 | | | | | | | 0 | | |
| (1) Abbott | | 44,5 | 0,92 | 2,1 | 31 | 0 | | | | | | | 31 | | | | | | | | | | | |
| (46) Erba Lachema | | 44,9 | 0,67 | 1,5 | 6 | 0 | | | | | | | 6 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 42,8 | 1,2 | 2,9 | 22 | 0 | | | | | | | 22 | | | | | | | | | | | |
| (60) Roche | | 44,8 | 1 | 2,3 | 58 | 0 | | | | | | | 58 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 44,5 | 1,8 | 3,9 | 16 | 0 | | | | | | | 16 | | | | | | | | | | | |
| (179) Siemens | | 44,6 | 0,67 | 1,5 | 5 | 0 | | | | | | | 5 | | | | | | | | | | | |
| Ostatní | | | | | 7 | 0 | | | | | | | 7 | | | | | | | | | | | |
| | | | | | | | 1x 12, 1x 85, 2x 149, 1x 166, 2x 177 | | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 32,2 | 1,5 | 4,8 | 145 | | CVP | 32,2 | 0,31 | 10% | 28,9 | 35,5 | 145 | 140 | 97 | | | | | | | 0 | | |
| (1) Abbott | | 31,3 | 0,55 | 1,7 | 31 | 0 | | | | | | | 31 | | | | | | | | | | | |
| (46) Erba Lachema | | 33,2 | 1,8 | 5,4 | 6 | 0 | | | | | | | 6 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 31 | 0,95 | 3,1 | 22 | 0 | | | | | | | 22 | | | | | | | | | | | |
| (60) Roche | | 33,4 | 1,1 | 3,3 | 58 | 0 | | | | | | | 58 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 31,8 | 1,8 | 5,8 | 16 | 0 | | | | | | | 16 | | | | | | | | | | | |
| (179) Siemens | | 31,5 | 0,74 | 2,4 | 5 | 0 | | | | | | | 5 | | | | | | | | | | | |
| Ostatní | | | | | 7 | 0 | | | | | | | 7 | | | | | | | | | | | |
| | | | | | | | 1x 12, 1x 85, 2x 149, 1x 166, 2x 177 | | | | | | | | | | | | | | | | | |
| (31) **Albumin (elfo)** | [-] | | | | 35 | | | | | | | | 35 | 35 | 100 | | | | | | | 0 | | |
| **Vzorek A** | | 0,631 | 0,045 | 7,1 | 35 | | CVP | 0,631 | 0,019 | 15% | 0,536 | 0,726 | 35 | 35 | 100 | | | | | | | 0 | | |
| (34) Sebia | | 0,645 | 0,033 | 5,1 | 29 | 0 | | | | | | | 29 | | | | | | | | | | | |
| (213) Interlab Srl | | 0,566 | 0,006 | 1 | 5 | 0 | | | | | | | 5 | | | | | | | | | | | |
| Ostatní | | | | | 1 | 0 | | | | | | | 1 | | | | | | | | | | | |
| | | | | | | | 1x 0 | | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 0,644 | 0,03 | 4,6 | 35 | | CVP | 0,644 | 0,012 | 15% | 0,547 | 0,741 | 35 | 35 | 100 | | | | | | | 0 | | |
| (34) Sebia | | 0,65 | 0,026 | 4 | 29 | 0 | | | | | | | 29 | | | | | | | | | | | |
| (213) Interlab Srl | | 0,614 | 0,021 | 3,4 | 5 | 0 | | | | | | | 5 | | | | | | | | | | | |
| Ostatní | | | | | 1 | 0 | | | | | | | 1 | | | | | | | | | | | |
| | | | | | | | 1x 0 | | | | | | | | | | | | | | | | | |
| (21) **ALP** | [µkat/L] | | | | 152 | | | | | | | | 141 | 131 | 93 | | | | | | | 152 | 127 | 84 |
| **Vzorek A** | | 0,784 | 0,061 | 7,8 | 152 | | | | | | | | 141 | 134 | 95 | CRV | 0,828 | 0,035 | 18% | 0,678 | 0,978 | 152 | 148 | 97 |
| (1) Abbott | | 0,831 | 0,05 | 6 | 34 | 0 | CVPG | 0,831 | 0,021 | 14% | 0,714 | 0,948 | 34 | | | | | | | | | 34 | | |
| (46) Erba Lachema | | 0,76 | 0,059 | 7,8 | 7 | 0 | CVPG | 0,76 | 0,058 | 14% | 0,653 | 0,867 | 7 | | | | | | | | | 7 | | |
| (58) Beckman Coulter (AU) | | 0,734 | 0,046 | 6,2 | 22 | 0 | CVPG | 0,734 | 0,024 | 14% | 0,631 | 0,837 | 22 | | | | | | | | | 22 | | |
| (60) Roche | | 0,776 | 0,048 | 6,1 | 60 | 0 | CVPG | 0,776 | 0,015 | 14% | 0,667 | 0,885 | 60 | | | | | | | | | 60 | | |
| (162) Siemens (Atellica) | | 0,794 | 0,039 | 4,9 | 18 | 0 | CVPG | 0,794 | 0,022 | 14% | 0,682 | 0,906 | 18 | | | | | | | | | 18 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | 0 | | | | | | | | | 11 | | |
| | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 3x 179 | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 3x 179 | | | | | | | | |
| **Vzorek B** | | 0,747 | 0,058 | 7,7 | 152 | | | | | | | | 141 | 133 | 94 | CRV | 0,691 | 0,019 | 18% | 0,566 | 0,816 | 152 | 130 | 86 |
| (1) Abbott | | 0,794 | 0,045 | 5,7 | 34 | 0 | CVPG | 0,794 | 0,019 | 14% | 0,682 | 0,906 | 34 | | | | | | | | | 34 | | |
| (46) Erba Lachema | | 0,74 | 0,089 | 12 | 7 | 0 | CVPG | 0,74 | 0,086 | 14% | 0,636 | 0,844 | 7 | | | | | | | | | 7 | | |
| (58) Beckman Coulter (AU) | | 0,759 | 0,047 | 6,2 | 22 | 0 | CVPG | 0,759 | 0,025 | 14% | 0,652 | 0,866 | 22 | | | | | | | | | 22 | | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS3/24 - Analyty krevního séra

Stop termín: 26.7.2024

Nastavení: skupiny - R (výrobce reagencií); minimální četnost skupin n = 5

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost | | | | | | | | Návaznost | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
| (60) Roche | | 0,726 | 0,052 | 7,1 | 60 | 0 | CVPG | 0,726 | 0,016 | 14% | 0,624 | 0,828 | 60 | | | | | | | | | 60 | | |
| (162) Siemens (Atellica) | | 0,728 | 0,038 | 5,3 | 18 | 0 | CVPG | 0,728 | 0,022 | 14% | 0,626 | 0,83 | 18 | | | | | | | | | 18 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | 0 | | | | | | | | | 11 | | |
| | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 3x 179 | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 3x 179 | | | | | | | | |
| (24) **ALT** | [µkat/L] | | | | 152 | | | | | | | | 0 | | | | | | | | | 152 | 145 | 95 |
| **Vzorek A** | | 1,7 | 0,092 | 5,4 | 152 | | | | | | | | 0 | | | CRV | 1,702 | 0,045 | 15% | 1,44 | 1,96 | 152 | 150 | 99 |
| (1) Abbott | | 1,73 | 0,058 | 3,4 | 34 | 0 | | | | | | | | | | | | | | | | 34 | | |
| (46) Erba Lachema | | 1,8 | 0,007 | 0,41 | 6 | 0 | | | | | | | | | | | | | | | | 6 | | |
| (58) Beckman Coulter (AU) | | 1,7 | 0,051 | 3 | 21 | 0 | | | | | | | | | | | | | | | | 21 | | |
| (60) Roche | | 1,63 | 0,049 | 3 | 62 | 0 | | | | | | | | | | | | | | | | 62 | | |
| (162) Siemens (Atellica) | | 1,77 | 0,037 | 2,1 | 18 | 0 | | | | | | | | | | | | | | | | 18 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | | | | | | | | | | 11 | | |
| | | | | | | | | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 3x 179 | | | | | | | | |
| **Vzorek B** | | 1,2 | 0,068 | 5,7 | 152 | | | | | | | | 0 | | | CRV | 1,164 | 0,031 | 15% | 0,989 | 1,34 | 152 | 145 | 95 |
| (1) Abbott | | 1,19 | 0,053 | 4,5 | 34 | 0 | | | | | | | | | | | | | | | | 34 | | |
| (46) Erba Lachema | | 1,27 | 0,03 | 2,3 | 6 | 0 | | | | | | | | | | | | | | | | 6 | | |
| (58) Beckman Coulter (AU) | | 1,21 | 0,048 | 4 | 21 | 0 | | | | | | | | | | | | | | | | 21 | | |
| (60) Roche | | 1,16 | 0,033 | 2,9 | 62 | 0 | | | | | | | | | | | | | | | | 62 | | |
| (162) Siemens (Atellica) | | 1,28 | 0,036 | 2,8 | 18 | 0 | | | | | | | | | | | | | | | | 18 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | | | | | | | | | | 11 | | |
| | | | | | | | | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 3x 179 | | | | | | | | |
| (23) **AST** | [µkat/L] | | | | 152 | | | | | | | | 0 | | | | | | | | | 152 | 149 | 98 |
| **Vzorek A** | | 1,48 | 0,069 | 4,6 | 152 | | | | | | | | 0 | | | CRV | 1,473 | 0,044 | 15% | 1,25 | 1,7 | 152 | 149 | 98 |
| (1) Abbott | | 1,52 | 0,039 | 2,6 | 34 | 0 | | | | | | | | | | | | | | | | 34 | | |
| (46) Erba Lachema | | 1,45 | 0,045 | 3,1 | 6 | 0 | | | | | | | | | | | | | | | | 6 | | |
| (58) Beckman Coulter (AU) | | 1,55 | 0,061 | 3,9 | 21 | 0 | | | | | | | | | | | | | | | | 21 | | |
| (60) Roche | | 1,44 | 0,055 | 3,8 | 62 | 0 | | | | | | | | | | | | | | | | 62 | | |
| (162) Siemens (Atellica) | | 1,49 | 0,038 | 2,5 | 18 | 0 | | | | | | | | | | | | | | | | 18 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | | | | | | | | | | 11 | | |
| | | | | | | | | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 3x 179 | | | | | | | | |
| **Vzorek B** | | 2,03 | 0,082 | 4 | 152 | | | | | | | | 0 | | | CRV | 2,017 | 0,044 | 15% | 1,71 | 2,32 | 152 | 151 | 99 |
| (1) Abbott | | 2,04 | 0,047 | 2,3 | 34 | 0 | | | | | | | | | | | | | | | | 34 | | |
| (46) Erba Lachema | | 1,99 | 0,037 | 1,9 | 6 | 0 | | | | | | | | | | | | | | | | 6 | | |
| (58) Beckman Coulter (AU) | | 2,13 | 0,087 | 4,1 | 21 | 0 | | | | | | | | | | | | | | | | 21 | | |
| (60) Roche | | 1,98 | 0,065 | 3,3 | 62 | 0 | | | | | | | | | | | | | | | | 62 | | |
| (162) Siemens (Atellica) | | 2,07 | 0,033 | 1,6 | 18 | 0 | | | | | | | | | | | | | | | | 18 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | | | | | | | | | | 11 | | |
| | | | | | | | | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 3x 179 | | | | | | | | |
| (13) **Bilirubin celkový** | [µmol/L] | | | | 152 | | | | | | | | 0 | | | | | | | | | 152 | 152 | 100 |
| **Vzorek A** | | 21,7 | 2,3 | 11 | 152 | | | | | | | | 0 | | | CRV | 21,42 | 0,57 | 26% | 15,8 | 27 | 152 | 152 | 100 |
| (1) Abbott | | 22,6 | 1,4 | 6,1 | 34 | 0 | | | | | | | | | | | | | | | | 34 | | |
| (46) Erba Lachema | | 23,3 | 0,22 | 0,96 | 5 | 0 | | | | | | | | | | | | | | | | 5 | | |
| (58) Beckman Coulter (AU) | | 24,2 | 0,65 | 2,7 | 19 | 0 | | | | | | | | | | | | | | | | 19 | | |
| (60) Roche | | 19,6 | 0,74 | 3,7 | 62 | 0 | | | | | | | | | | | | | | | | 62 | | |
| (162) Siemens (Atellica) | | 23,4 | 1,4 | 5,9 | 18 | 0 | | | | | | | | | | | | | | | | 18 | | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS3/24 - Analyty krevního séra

Stop termín: 26.7.2024

Nastavení: skupiny - R (výrobce reagencií); minimální četnost skupin n = 5

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Návaznost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ostatní | | | | | 14 | 0 | | | | | | | | | | | | | | | | 14 | | |
| | | | | | | | | | | | | | | | | 1x 12, 2x 70, 1x 85, 2x 149, 1x 158, 4x 177, 3x 179 | | | | | | | | |
| **Vzorek B** | | 51,2 | 4,5 | 8,7 | 152 | | | | | | | | 0 | | | CRV | 50,2 | 1,2 | 26% | 37,1 | 63,3 | 152 | 152 | 100 |
| (1) Abbott | | 52 | 2,4 | 4,6 | 34 | 0 | | | | | | | | | | | | | | | | 34 | | |
| (46) Erba Lachema | | 57,1 | 0,15 | 0,26 | 5 | 0 | | | | | | | | | | | | | | | | 5 | | |
| (58) Beckman Coulter (AU) | | 54,5 | 1,7 | 3,1 | 19 | 0 | | | | | | | | | | | | | | | | 19 | | |
| (60) Roche | | 47,5 | 1,7 | 3,6 | 62 | 0 | | | | | | | | | | | | | | | | 62 | | |
| (162) Siemens (Atellica) | | 55,7 | 3,3 | 6 | 18 | 0 | | | | | | | | | | | | | | | | 18 | | |
| Ostatní | | | | | 14 | 0 | | | | | | | | | | | | | | | | 14 | | |
| | | | | | | | | | | | | | | | | 1x 12, 2x 70, 1x 85, 2x 149, 1x 158, 4x 177, 3x 179 | | | | | | | | |
| (14) **Bilirubin přímý** | [µmol/L] | | | | 126 | | | | | | | | 110 | 106 | 96 | | | | | | | 0 | | |
| **Vzorek A** | | 6,47 | 1,2 | 18 | 126 | | | | | | | | 110 | 106 | 96 | | | | | | | 0 | | |
| (1) Abbott | | 6,46 | 0,31 | 4,8 | 28 | 0 | CVPG | 6,46 | 0,14 | 20% | 5,16 | 7,76 | 28 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 3,93 | 0,39 | 9,8 | 19 | 0 | CVPG | 3,93 | 0,22 | 20% | 3,14 | 4,72 | 19 | | | | | | | | | | | |
| (60) Roche | | 6,82 | 0,49 | 7,2 | 47 | 0 | CVPG | 6,82 | 0,17 | 20% | 5,45 | 8,19 | 47 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 8,01 | 0,36 | 4,5 | 16 | 0 | CVPG | 8,01 | 0,22 | 20% | 6,4 | 9,62 | 16 | | | | | | | | | | | |
| Ostatní | | | | | 16 | 0 | | | | | | | 0 | | | | | | | | | | | |
| | | | | | | | 1x 12, 1x 18, 4x 46, 2x 70, 1x 149, 1x 158, 3x 177, 3x 179 | | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 11,8 | 4,8 | 41 | 126 | | | | | | | | 110 | 107 | 97 | | | | | | | 0 | | |
| (1) Abbott | | 7,79 | 0,46 | 5,8 | 28 | 0 | CVPG | 7,79 | 0,21 | 20% | 6,23 | 9,35 | 28 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 8,07 | 0,93 | 11 | 19 | 0 | CVPG | 8,07 | 0,52 | 20% | 6,45 | 9,69 | 19 | | | | | | | | | | | |
| (60) Roche | | 13,8 | 1,4 | 10 | 47 | 0 | CVPG | 13,8 | 0,5 | 20% | 11 | 16,6 | 47 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 19,4 | 1,5 | 7,9 | 16 | 0 | CVPG | 19,4 | 0,94 | 20% | 15,5 | 23,3 | 16 | | | | | | | | | | | |
| Ostatní | | | | | 16 | 0 | | | | | | | 0 | | | | | | | | | | | |
| | | | | | | | 1x 12, 1x 18, 4x 46, 2x 70, 1x 149, 1x 158, 3x 177, 3x 179 | | | | | | | | | | | | | | | | | |
| (9) **Celková bílkovina** | [g/L] | | | | 147 | | | | | | | | 0 | | | | | | | | | 147 | 145 | 99 |
| **Vzorek A** | | 69,9 | 1,8 | 2,6 | 147 | | | | | | | | 0 | | | CRV | 69,9 | 1,5 | 9% | 63,6 | 76,2 | 147 | 145 | 99 |
| (1) Abbott | | 71 | 1,7 | 2,4 | 30 | 0 | | | | | | | | | | | | | | | | 30 | | |
| (58) Beckman Coulter (AU) | | 69,3 | 1,4 | 2,1 | 22 | 0 | | | | | | | | | | | | | | | | 22 | | |
| (60) Roche | | 69,5 | 1,7 | 2,4 | 60 | 0 | | | | | | | | | | | | | | | | 60 | | |
| (162) Siemens (Atellica) | | 69,8 | 1,5 | 2,2 | 16 | 0 | | | | | | | | | | | | | | | | 16 | | |
| (179) Siemens | | 68,9 | 1,6 | 2,4 | 6 | 0 | | | | | | | | | | | | | | | | 6 | | |
| Ostatní | | | | | 13 | 0 | | | | | | | | | | | | | | | | 13 | | |
| | | | | | | | | | | | | | | | | 1x 12, 3x 46, 2x 49, 1x 85, 2x 149, 4x 177 | | | | | | | | |
| **Vzorek B** | | 49,6 | 1,3 | 2,6 | 147 | | | | | | | | 0 | | | CRV | 51,1 | 1,1 | 9% | 46,5 | 55,7 | 147 | 146 | 99 |
| (1) Abbott | | 50,4 | 1,6 | 3,3 | 30 | 0 | | | | | | | | | | | | | | | | 30 | | |
| (58) Beckman Coulter (AU) | | 49 | 0,9 | 1,8 | 22 | 0 | | | | | | | | | | | | | | | | 22 | | |
| (60) Roche | | 49,5 | 1,1 | 2,2 | 60 | 0 | | | | | | | | | | | | | | | | 60 | | |
| (162) Siemens (Atellica) | | 49,5 | 0,92 | 1,9 | 16 | 0 | | | | | | | | | | | | | | | | 16 | | |
| (179) Siemens | | 49,3 | 1,1 | 2,3 | 6 | 0 | | | | | | | | | | | | | | | | 6 | | |
| Ostatní | | | | | 13 | 0 | | | | | | | | | | | | | | | | 13 | | |
| | | | | | | | | | | | | | | | | 1x 12, 3x 46, 2x 49, 1x 85, 2x 149, 4x 177 | | | | | | | | |
| (26) **CK** | [µkat/L] | | | | 139 | | | | | | | | 0 | | | | | | | | | 139 | 124 | 89 |
| **Vzorek A** | | 5,35 | 0,4 | 7,4 | 139 | | | | | | | | 0 | | | CRV | 6 | 0,17 | 20% | 4,8 | 7,2 | 139 | 129 | 93 |
| (1) Abbott | | 5,47 | 0,41 | 7,5 | 29 | 0 | | | | | | | | | | | | | | | | 29 | | |
| (46) Erba Lachema | | 5,42 | 0,67 | 12 | 8 | 0 | | | | | | | | | | | | | | | | 8 | | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS3/24 - Analyty krevního séra

Stop termín: 26.7.2024

Nastavení: skupiny - R (výrobce reagencií); minimální četnost skupin n = 5

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Návaznost AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (58) Beckman Coulter (AU) | | 5,44 | 0,4 | 7,4 | 20 | 0 | | | | | | | | | | | | | | 20 | | |
| (60) Roche | | 5,26 | 0,33 | 6,3 | 57 | 0 | | | | | | | | | | | | | | 57 | | |
| (162) Siemens (Atellica) | | 5,2 | 0,33 | 6,3 | 14 | 0 | | | | | | | | | | | | | | 14 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | | | | | | | | 11 | | |
| | | | | | | | | | | | | | | | 1x 12, 2x 149, 4x 177, 4x 179 | | | | | | | |
| **Vzorek B** | | 1,92 | 0,15 | 7,6 | 139 | | | | | | | 0 | | | CRV 2,129 | 0,053 | 20% | 1,7 | 2,56 | 139 | 129 | 93 |
| (1) Abbott | | 1,94 | 0,15 | 7,5 | 29 | 0 | | | | | | | | | | | | | | 29 | | |
| (46) Erba Lachema | | 1,93 | 0,2 | 10 | 8 | 0 | | | | | | | | | | | | | | 8 | | |
| (58) Beckman Coulter (AU) | | 1,94 | 0,16 | 8,2 | 20 | 0 | | | | | | | | | | | | | | 20 | | |
| (60) Roche | | 1,9 | 0,14 | 7,2 | 57 | 0 | | | | | | | | | | | | | | 57 | | |
| (162) Siemens (Atellica) | | 1,89 | 0,14 | 7,2 | 14 | 0 | | | | | | | | | | | | | | 14 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | | | | | | | | 11 | | |
| | | | | | | | | | | | | | | | 1x 12, 2x 149, 4x 177, 4x 179 | | | | | | | |
| (2) **Draselný kation** | [mmol/L] | | | | 154 | | | | | | | 154 | 151 | 98 | | | | | | 0 | | |
| **Vzorek A** | | 5,69 | 0,13 | 2,3 | 154 | | CRV 5,621 | 0,084 | 7% | 5,22 | 6,02 | 154 | 152 | 99 | | | | | | 0 | | |
| (1) Abbott | | 5,62 | 0,11 | 1,9 | 35 | 0 | | | | | | 35 | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 5,58 | 0,11 | 2 | 22 | 0 | | | | | | 22 | | | | | | | | | | |
| (60) Roche | | 5,75 | 0,089 | 1,5 | 63 | 0 | | | | | | 63 | | | | | | | | | | |
| (162) Siemens (Atellica) | | 5,75 | 0,11 | 1,8 | 18 | 0 | | | | | | 18 | | | | | | | | | | |
| (179) Siemens | | 5,78 | 0,067 | 1,2 | 5 | 0 | | | | | | 5 | | | | | | | | | | |
| Ostatní | | | | | 11 | 0 | | | | | | 11 | | | | | | | | | | |
| | | | | | | | 1x 11, 1x 12, 2x 46, 1x 77, 1x 85, 2x 149, 3x 177 | | | | | | | | | | | | | | | |
| **Vzorek B** | | 3,64 | 0,077 | 2,1 | 154 | | CVP 3,64 | 0,015 | 6% | 3,42 | 3,86 | 154 | 151 | 98 | | | | | | 0 | | |
| (1) Abbott | | 3,6 | 0,05 | 1,4 | 35 | 0 | | | | | | 35 | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 3,56 | 0,053 | 1,5 | 22 | 0 | | | | | | 22 | | | | | | | | | | |
| (60) Roche | | 3,67 | 0,062 | 1,7 | 63 | 0 | | | | | | 63 | | | | | | | | | | |
| (162) Siemens (Atellica) | | 3,66 | 0,054 | 1,5 | 18 | 0 | | | | | | 18 | | | | | | | | | | |
| (179) Siemens | | 3,69 | 0,007 | 0,2 | 5 | 0 | | | | | | 5 | | | | | | | | | | |
| Ostatní | | | | | 11 | 0 | | | | | | 11 | | | | | | | | | | |
| | | | | | | | 1x 11, 1x 12, 2x 46, 1x 77, 1x 85, 2x 149, 3x 177 | | | | | | | | | | | | | | | |
| (5) **Fosfáty anorganické** | [mmol/L] | | | | 139 | | | | | | | 139 | 134 | 96 | | | | | | 0 | | |
| **Vzorek A** | | 1,22 | 0,037 | 3 | 139 | | CVP 1,22 | 0,008 | 10% | 1,09 | 1,35 | 139 | 137 | 99 | | | | | | 0 | | |
| (1) Abbott | | 1,19 | 0,027 | 2,3 | 31 | 0 | | | | | | 31 | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 1,22 | 0,028 | 2,2 | 22 | 0 | | | | | | 22 | | | | | | | | | | |
| (60) Roche | | 1,22 | 0,03 | 2,4 | 55 | 0 | | | | | | 55 | | | | | | | | | | |
| (162) Siemens (Atellica) | | 1,23 | 0,033 | 2,6 | 16 | 0 | | | | | | 16 | | | | | | | | | | |
| (179) Siemens | | 1,22 | 0,03 | 2,4 | 5 | 0 | | | | | | 5 | | | | | | | | | | |
| Ostatní | | | | | 10 | 0 | | | | | | 10 | | | | | | | | | | |
| | | | | | | | 1x 12, 4x 46, 2x 149, 3x 177 | | | | | | | | | | | | | | | |
| **Vzorek B** | | 0,787 | 0,028 | 3,5 | 139 | | CVP 0,787 | 0,006 | 10% | 0,708 | 0,866 | 139 | 134 | 96 | | | | | | 0 | | |
| (1) Abbott | | 0,773 | 0,02 | 2,6 | 31 | 0 | | | | | | 31 | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 0,79 | 0,014 | 1,8 | 22 | 0 | | | | | | 22 | | | | | | | | | | |
| (60) Roche | | 0,79 | 0,027 | 3,4 | 55 | 0 | | | | | | 55 | | | | | | | | | | |
| (162) Siemens (Atellica) | | 0,796 | 0,024 | 3 | 16 | 0 | | | | | | 16 | | | | | | | | | | |
| (179) Siemens | | 0,805 | 0,037 | 4,6 | 5 | 0 | | | | | | 5 | | | | | | | | | | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS3/24 - Analyty krevního séra

Stop termín: 26.7.2024

Nastavení: skupiny - R (výrobce reagencií); minimální četnost skupin n = 5

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Návaznost AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ostatní | | | | | 10 | 0 | | | | | | 10 | | | | | | | | | | |
| | | | | | | | 1x 12, 4x 46, 2x 149, 3x 177 | | | | | | | | | | | | | | | |
| (27) **GGT** | [µkat/L] | | | | 150 | | | | | | | 0 | | | | | | | | 150 | 150 | 100 |
| **Vzorek A** | | 0,983 | 0,031 | 3,2 | 150 | | | | | | | 0 | | | CRV | 1,053 | 0,027 | 21% | 0,831 | 1,28 | 150 | 150 | 100 |
| (1) Abbott | | 1 | 0,041 | 4 | 33 | 0 | | | | | | | | | | | | | | 33 | | |
| (46) Erba Lachema | | 1,02 | 0,03 | 2,9 | 6 | 0 | | | | | | | | | | | | | | 6 | | |
| (58) Beckman Coulter (AU) | | 0,967 | 0,027 | 2,8 | 22 | 0 | | | | | | | | | | | | | | 22 | | |
| (60) Roche | | 0,978 | 0,023 | 2,3 | 60 | 0 | | | | | | | | | | | | | | 60 | | |
| (162) Siemens (Atellica) | | 0,981 | 0,017 | 1,8 | 18 | 0 | | | | | | | | | | | | | | 18 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | | | | | | | | 11 | | |
| | | | | | | | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 3x 179 | | | | | | | |
| **Vzorek B** | | 0,981 | 0,031 | 3,1 | 150 | | | | | | | 0 | | | CRV | 1,017 | 0,025 | 21% | 0,803 | 1,24 | 150 | 150 | 100 |
| (1) Abbott | | 0,988 | 0,039 | 4 | 33 | 0 | | | | | | | | | | | | | | 33 | | |
| (46) Erba Lachema | | 1,02 | 0,015 | 1,5 | 6 | 0 | | | | | | | | | | | | | | 6 | | |
| (58) Beckman Coulter (AU) | | 0,962 | 0,023 | 2,4 | 22 | 0 | | | | | | | | | | | | | | 22 | | |
| (60) Roche | | 0,983 | 0,024 | 2,5 | 60 | 0 | | | | | | | | | | | | | | 60 | | |
| (162) Siemens (Atellica) | | 0,975 | 0,028 | 2,8 | 18 | 0 | | | | | | | | | | | | | | 18 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | | | | | | | | 11 | | |
| | | | | | | | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 3x 179 | | | | | | | |
| (16) **Glukóza** | [mmol/L] | | | | 155 | | | | | | | 0 | | | | | | | | 155 | 146 | 94 |
| **Vzorek A** | | 4,49 | 0,11 | 2,5 | 155 | | | | | | | 0 | | | CRV | 4,656 | 0,047 | 8% | 4,28 | 5,03 | 155 | 148 | 95 |
| (1) Abbott | | 4,42 | 0,12 | 2,8 | 31 | 0 | | | | | | | | | | | | | | 31 | | |
| (46) Erba Lachema | | 4,73 | 0,19 | 3,9 | 9 | 0 | | | | | | | | | | | | | | 9 | | |
| (58) Beckman Coulter (AU) | | 4,47 | 0,1 | 2,3 | 21 | 0 | | | | | | | | | | | | | | 21 | | |
| (60) Roche | | 4,5 | 0,084 | 1,9 | 62 | 0 | | | | | | | | | | | | | | 62 | | |
| (162) Siemens (Atellica) | | 4,46 | 0,069 | 1,5 | 18 | 0 | | | | | | | | | | | | | | 18 | | |
| Ostatní | | | | | 14 | 0 | | | | | | | | | | | | | | 14 | | |
| | | | | | | | | | | | | | | | 1x 0, 1x 12, 1x 49, 1x 75, 1x 85, 2x 149, 4x 177, 3x 179 | | | | | | | |
| **Vzorek B** | | 6,86 | 0,15 | 2,1 | 155 | | | | | | | 0 | | | CRV | 6,915 | 0,069 | 8% | 6,36 | 7,47 | 155 | 151 | 97 |
| (1) Abbott | | 6,78 | 0,14 | 2 | 31 | 0 | | | | | | | | | | | | | | 31 | | |
| (46) Erba Lachema | | 7,16 | 0,23 | 3,2 | 9 | 0 | | | | | | | | | | | | | | 9 | | |
| (58) Beckman Coulter (AU) | | 6,88 | 0,17 | 2,5 | 21 | 0 | | | | | | | | | | | | | | 21 | | |
| (60) Roche | | 6,87 | 0,12 | 1,8 | 62 | 0 | | | | | | | | | | | | | | 62 | | |
| (162) Siemens (Atellica) | | 6,81 | 0,081 | 1,2 | 18 | 0 | | | | | | | | | | | | | | 18 | | |
| Ostatní | | | | | 14 | 0 | | | | | | | | | | | | | | 14 | | |
| | | | | | | | | | | | | | | | 1x 0, 1x 12, 1x 49, 1x 75, 1x 85, 2x 149, 4x 177, 3x 179 | | | | | | | |
| (7) **Hořčík celkový** | [mmol/L] | | | | 138 | | | | | | | 138 | 132 | 96 | | | | | | 0 | | |
| **Vzorek A** | | 1,51 | 0,045 | 3 | 138 | | CRV | 1,499 | 0,029 | 15% | 1,27 | 1,73 | 138 | 134 | 97 | | | | | 0 | | |
| (1) Abbott | | 1,54 | 0,073 | 4,7 | 31 | 0 | | | | | | | 31 | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 1,49 | 0,041 | 2,7 | 21 | 0 | | | | | | | 21 | | | | | | | | | |
| (60) Roche | | 1,52 | 0,028 | 1,9 | 55 | 0 | | | | | | | 55 | | | | | | | | | |
| (162) Siemens (Atellica) | | 1,48 | 0,031 | 2,1 | 16 | 0 | | | | | | | 16 | | | | | | | | | |
| (179) Siemens | | 1,48 | 0,037 | 2,5 | 5 | 0 | | | | | | | 5 | | | | | | | | | |
| Ostatní | | | | | 10 | 0 | | | | | | | 10 | | | | | | | | | |
| | | | | | | | 1x 12, 1x 46, 2x 77, 1x 85, 2x 149, 3x 177 | | | | | | | | | | | | | | | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS3/24 - Analyty krevního séra

Stop termín: 26.7.2024

Nastavení: skupiny - R (výrobce reagencií); minimální četnost skupin n = 5

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Návaznost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Vzorek B** | | 0,806 | 0,028 | 3,4 | 138 | | CVP | 0,806 | 0,006 | 11% | 0,717 | 0,895 | 138 | 133 | 96 | | | | | | | 0 | | |
| (1) Abbott | | 0,811 | 0,042 | 5,2 | 31 | 0 | | | | | | | 31 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 0,8 | 0,023 | 2,8 | 21 | 0 | | | | | | | 21 | | | | | | | | | | | |
| (60) Roche | | 0,811 | 0,02 | 2,5 | 55 | 0 | | | | | | | 55 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 0,793 | 0,019 | 2,4 | 16 | 0 | | | | | | | 16 | | | | | | | | | | | |
| (179) Siemens | | 0,795 | 0,007 | 0,93 | 5 | 0 | | | | | | | 5 | | | | | | | | | | | |
| Ostatní | | | | | 10 | 0 | | | | | | | 10 | | | | | | | | | | | |
| | | | | | | | 1x 12, 1x 46, 2x 77, 1x 85, 2x 149, 3x 177 | | | | | | | | | | | | | | | | | |
| (3) **Chloridový anion** | [mmol/L] | | | | 154 | | | | | | | | 154 | 151 | 98 | | | | | | | 0 | | |
| **Vzorek A** | | 115 | 3,3 | 2,9 | 154 | | CVP | 115 | 0,66 | 7% | 106 | 124 | 154 | 152 | 99 | | | | | | | 0 | | |
| (1) Abbott | | 118 | 2,2 | 1,9 | 35 | 0 | | | | | | | 35 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 115 | 1,9 | 1,7 | 22 | 0 | | | | | | | 22 | | | | | | | | | | | |
| (60) Roche | | 113 | 2,5 | 2,2 | 63 | 0 | | | | | | | 63 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 117 | 2,3 | 1,9 | 18 | 0 | | | | | | | 18 | | | | | | | | | | | |
| (179) Siemens | | 117 | 0,37 | 0,32 | 5 | 0 | | | | | | | 5 | | | | | | | | | | | |
| Ostatní | | | | | 11 | 0 | | | | | | | 11 | | | | | | | | | | | |
| | | | | | | | 1x 11, 1x 12, 3x 46, 1x 77, 2x 149, 3x 177 | | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 97,5 | 3,4 | 3,5 | 154 | | CVP | 97,5 | 0,67 | 7% | 90,6 | 105 | 154 | 151 | 98 | | | | | | | 0 | | |
| (1) Abbott | | 101 | 1,6 | 1,6 | 35 | 0 | | | | | | | 35 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 97,8 | 1,2 | 1,2 | 22 | 0 | | | | | | | 22 | | | | | | | | | | | |
| (60) Roche | | 94,9 | 2,2 | 2,3 | 63 | 0 | | | | | | | 63 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 99,7 | 2,5 | 2,5 | 18 | 0 | | | | | | | 18 | | | | | | | | | | | |
| (179) Siemens | | 98,5 | 0,74 | 0,75 | 5 | 0 | | | | | | | 5 | | | | | | | | | | | |
| Ostatní | | | | | 11 | 0 | | | | | | | 11 | | | | | | | | | | | |
| | | | | | | | 1x 11, 1x 12, 3x 46, 1x 77, 2x 149, 3x 177 | | | | | | | | | | | | | | | | | |
| (15) **Cholesterol** | [mmol/L] | | | | 143 | | | | | | | | 0 | | | | | | | | | 141 | 138 | 98 |
| **Vzorek A** | | 4,4 | 0,12 | 2,8 | 143 | | | | | | | | 0 | | | | | | | | | 141 | 138 | 98 |
| (1) Abbott | | 4,42 | 0,11 | 2,5 | 32 | 0 | | | | | | | | | | CRV | 4,483 | 0,045 | 9% | 4,07 | 4,89 | 32 | | |
| (46) Erba Lachema | | 4,48 | 0,18 | 4 | 7 | 0 | | | | | | | | | | CRV | 4,483 | 0,045 | 9% | 4,07 | 4,89 | 7 | | |
| (58) Beckman Coulter (AU) | | 4,48 | 0,14 | 3,2 | 22 | 0 | | | | | | | | | | CRV | 4,483 | 0,045 | 9% | 4,07 | 4,89 | 22 | | |
| (60) Roche | | 4,38 | 0,11 | 2,6 | 56 | 0 | | | | | | | | | | CRV | 4,483 | 0,045 | 9% | 4,07 | 4,89 | 56 | | |
| (162) Siemens (Atellica) | | 4,33 | 0,058 | 1,4 | 14 | 0 | | | | | | | | | | CRV | 4,483 | 0,045 | 9% | 4,07 | 4,89 | 14 | | |
| Ostatní | | | | | 12 | 0 | | | | | | | 0 | | | | | | | | | 10 | | |
| | | | | | | | 2x 149 | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 1x 178, 3x 179 | | | | | | | | |
| **Vzorek B** | | 3,17 | 0,096 | 3 | 143 | | | | | | | | 0 | | | | | | | | | 141 | 139 | 99 |
| (1) Abbott | | 3,19 | 0,096 | 3 | 32 | 0 | | | | | | | | | | CRV | 3,225 | 0,077 | 9% | 2,93 | 3,52 | 32 | | |
| (46) Erba Lachema | | 3,16 | 0,067 | 2,1 | 7 | 0 | | | | | | | | | | CRV | 3,225 | 0,077 | 9% | 2,93 | 3,52 | 7 | | |
| (58) Beckman Coulter (AU) | | 3,16 | 0,088 | 2,8 | 22 | 0 | | | | | | | | | | CRV | 3,225 | 0,077 | 9% | 2,93 | 3,52 | 22 | | |
| (60) Roche | | 3,15 | 0,086 | 2,7 | 56 | 0 | | | | | | | | | | CRV | 3,225 | 0,077 | 9% | 2,93 | 3,52 | 56 | | |
| (162) Siemens (Atellica) | | 3,25 | 0,062 | 1,9 | 14 | 0 | | | | | | | | | | CRV | 3,225 | 0,077 | 9% | 2,93 | 3,52 | 14 | | |
| Ostatní | | | | | 12 | 0 | | | | | | | 0 | | | | | | | | | 10 | | |
| | | | | | | | 2x 149 | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 1x 178, 3x 179 | | | | | | | | |
| (30) **Cholinesteráza** | [µkat/L] | | | | 44 | | | | | | | | 43 | 41 | 95 | | | | | | | 0 | | |
| **Vzorek A** | | 135 | 6,5 | 4,9 | 44 | | | | | | | | 43 | 41 | 95 | | | | | | | 0 | | |
| (1) Abbott | | 139 | 3,9 | 2,8 | 12 | 0 | CVP | 134 | 2,3 | 12% | 117 | 151 | 12 | | | | | | | | | | | |
| (46) Erba Lachema | | 134 | 9,8 | 7,3 | 8 | 0 | CVP | 134 | 2,3 | 12% | 117 | 151 | 8 | | | | | | | | | | | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS3/24 - Analyty krevního séra

Stop termín: 26.7.2024

Nastavení: skupiny - R (výrobce reagencií); minimální četnost skupin n = 5

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Návaznost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (58) Beckman Coulter (AU) | | 132 | 7,4 | 5,6 | 5 | 0 | CVP | 134 | 2,3 | 12% | 117 | 151 | 5 | | | | | | | | | | | |
| (60) Roche | | 132 | 3,9 | 2,9 | 13 | 0 | CVP | 134 | 2,3 | 12% | 117 | 151 | 13 | | | | | | | | | | | |
| Ostatní | | | | | 6 | 0 | | | | | | | 5 | | | | | | | | | | | |
| | | | | | | | 1x 5, 2x 12, 1x 116, 1x 162, 1x 179 | | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 98,7 | 4,5 | 4,5 | 44 | | | | | | | | 43 | 41 | 95 | | | | | | | 0 | | |
| (1) Abbott | | 101 | 2,9 | 2,9 | 12 | 0 | CVP | 98,5 | 1,6 | 12% | 86,6 | 111 | 12 | | | | | | | | | | | |
| (46) Erba Lachema | | 97,4 | 5,5 | 5,6 | 8 | 0 | CVP | 98,5 | 1,6 | 12% | 86,6 | 111 | 8 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 97 | 5,9 | 6,1 | 5 | 0 | CVP | 98,5 | 1,6 | 12% | 86,6 | 111 | 5 | | | | | | | | | | | |
| (60) Roche | | 97,5 | 2,8 | 2,9 | 13 | 0 | CVP | 98,5 | 1,6 | 12% | 86,6 | 111 | 13 | | | | | | | | | | | |
| Ostatní | | | | | 6 | 0 | | | | | | | 5 | | | | | | | | | | | |
| | | | | | | | 1x 5, 2x 12, 1x 116, 1x 162, 1x 179 | | | | | | | | | | | | | | | | | |
| (19) **Kreatinin** | [µmol/L] | | | | 153 | | | | | | | | 0 | | | | | | | | | 153 | 137 | 90 |
| **Vzorek A** | | 58,8 | 3,7 | 6,4 | 153 | | | | | | | | 0 | | | CRV | 58,14 | 0,58 | 13% | 50,5 | 65,7 | 153 | 137 | 90 |
| (1) Abbott | | 56,5 | 3,7 | 6,5 | 33 | 0 | | | | | | | | | | | | | | | | 33 | | |
| (46) Erba Lachema | | 56,7 | 2,5 | 4,4 | 7 | 0 | | | | | | | | | | | | | | | | 7 | | |
| (58) Beckman Coulter (AU) | | 58,4 | 1,8 | 3,1 | 20 | 0 | | | | | | | | | | | | | | | | 20 | | |
| (60) Roche | | 61,1 | 4,7 | 7,6 | 63 | 0 | | | | | | | | | | | | | | | | 63 | | |
| (162) Siemens (Atellica) | | 57,7 | 2,9 | 5 | 18 | 0 | | | | | | | | | | | | | | | | 18 | | |
| Ostatní | | | | | 12 | 0 | | | | | | | | | | | | | | | | 12 | | |
| | | | | | | | | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 4x 179 | | | | | | | | |
| **Vzorek B** | | 187 | 6,5 | 3,5 | 153 | | | | | | | | 0 | | | CRV | 184,5 | 1,8 | 13% | 160 | 209 | 153 | 150 | 98 |
| (1) Abbott | | 182 | 4,1 | 2,2 | 33 | 0 | | | | | | | | | | | | | | | | 33 | | |
| (46) Erba Lachema | | 188 | 11 | 5,7 | 7 | 0 | | | | | | | | | | | | | | | | 7 | | |
| (58) Beckman Coulter (AU) | | 190 | 4,7 | 2,5 | 20 | 0 | | | | | | | | | | | | | | | | 20 | | |
| (60) Roche | | 189 | 6,4 | 3,4 | 63 | 0 | | | | | | | | | | | | | | | | 63 | | |
| (162) Siemens (Atellica) | | 186 | 6,7 | 3,6 | 18 | 0 | | | | | | | | | | | | | | | | 18 | | |
| Ostatní | | | | | 12 | 0 | | | | | | | | | | | | | | | | 12 | | |
| | | | | | | | | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 4x 179 | | | | | | | | |
| (17) **Kyselina močová** | [µmol/L] | | | | 150 | | | | | | | | 0 | | | | | | | | | 150 | 148 | 99 |
| **Vzorek A** | | 395 | 12 | 3 | 150 | | | | | | | | 0 | | | CRV | 391,8 | 3,9 | 12% | 344 | 439 | 150 | 148 | 99 |
| (1) Abbott | | 390 | 8,7 | 2,2 | 33 | 0 | | | | | | | | | | | | | | | | 33 | | |
| (46) Erba Lachema | | 407 | 16 | 3,9 | 6 | 0 | | | | | | | | | | | | | | | | 6 | | |
| (58) Beckman Coulter (AU) | | 403 | 7 | 1,7 | 21 | 0 | | | | | | | | | | | | | | | | 21 | | |
| (60) Roche | | 389 | 9,1 | 2,3 | 60 | 0 | | | | | | | | | | | | | | | | 60 | | |
| (162) Siemens (Atellica) | | 404 | 5,5 | 1,4 | 17 | 0 | | | | | | | | | | | | | | | | 17 | | |
| Ostatní | | | | | 13 | 0 | | | | | | | | | | | | | | | | 13 | | |
| | | | | | | | | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 1x 178, 4x 179 | | | | | | | | |
| **Vzorek B** | | 291 | 11 | 3,6 | 150 | | | | | | | | 0 | | | CRV | 288,5 | 2,9 | 12% | 253 | 324 | 150 | 149 | 99 |
| (1) Abbott | | 287 | 8,4 | 2,9 | 33 | 0 | | | | | | | | | | | | | | | | 33 | | |
| (46) Erba Lachema | | 302 | 14 | 4,8 | 6 | 0 | | | | | | | | | | | | | | | | 6 | | |
| (58) Beckman Coulter (AU) | | 303 | 4,4 | 1,5 | 21 | 0 | | | | | | | | | | | | | | | | 21 | | |
| (60) Roche | | 286 | 7,6 | 2,7 | 60 | 0 | | | | | | | | | | | | | | | | 60 | | |
| (162) Siemens (Atellica) | | 298 | 5,2 | 1,7 | 17 | 0 | | | | | | | | | | | | | | | | 17 | | |
| Ostatní | | | | | 13 | 0 | | | | | | | | | | | | | | | | 13 | | |
| | | | | | | | | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 1x 178, 4x 179 | | | | | | | | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS3/24 - Analyty krevního séra

Stop termín: 26.7.2024

Nastavení: skupiny - R (výrobce reagencií); minimální četnost skupin n = 5

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Návaznost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (12) **Laktát** | [mmol/L] | | | | 64 | | | | | | | | 64 | 61 | 95 | | | | | | | 0 | | |
| **Vzorek A** | | 3,98 | 0,079 | 2 | 64 | | CVP | 3,98 | 0,024 | 15% | 3,38 | 4,58 | 64 | 64 | 100 | | | | | | | 0 | | |
| (1) Abbott | | 3,96 | 0,059 | 1,5 | 6 | 0 | | | | | | | 6 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 3,96 | 0,037 | 0,94 | 9 | 0 | | | | | | | 9 | | | | | | | | | | | |
| (60) Roche | | 3,98 | 0,064 | 1,6 | 25 | 0 | | | | | | | 25 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 4,03 | 0,068 | 1,7 | 11 | 0 | | | | | | | 11 | | | | | | | | | | | |
| Ostatní | | | | | 13 | 0 | | | | | | | 13 | | | | | | | | | | | |
| | | | | | | | 2x 12, 1x 49, 3x 61, 1x 75, 1x 115, 1x 116, 2x 149, 2x 179 | | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 0,981 | 0,048 | 4,9 | 64 | | CVP | 0,981 | 0,015 | 15% | 0,833 | 1,13 | 64 | 61 | 95 | | | | | | | 0 | | |
| (1) Abbott | | 1,01 | 0,052 | 5,2 | 6 | 0 | | | | | | | 6 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 0,935 | 0,022 | 2,4 | 9 | 0 | | | | | | | 9 | | | | | | | | | | | |
| (60) Roche | | 0,985 | 0,028 | 2,9 | 25 | 0 | | | | | | | 25 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 1,01 | 0,021 | 2 | 11 | 0 | | | | | | | 11 | | | | | | | | | | | |
| Ostatní | | | | | 13 | 0 | | | | | | | 13 | | | | | | | | | | | |
| | | | | | | | 2x 12, 1x 49, 3x 61, 1x 75, 1x 115, 1x 116, 2x 149, 2x 179 | | | | | | | | | | | | | | | | | |
| (28) **LD** | [µkat/L] | | | | 120 | | | | | | | | 0 | | | | | | | | | 120 | 119 | 99 |
| **Vzorek A** | | 3,36 | 0,13 | 3,8 | 120 | | | | | | | | 0 | | | CRV | 3,368 | 0,086 | 18% | 2,76 | 3,98 | 120 | 119 | 99 |
| (1) Abbott | | 3,29 | 0,2 | 6,1 | 24 | 0 | | | | | | | | | | | | | | | | 24 | | |
| (46) Erba Lachema | | 3,64 | 0,12 | 3,3 | 5 | 0 | | | | | | | | | | | | | | | | 5 | | |
| (58) Beckman Coulter (AU) | | 3,36 | 0,1 | 3,1 | 19 | 0 | | | | | | | | | | | | | | | | 19 | | |
| (60) Roche | | 3,34 | 0,09 | 2,7 | 48 | 0 | | | | | | | | | | | | | | | | 48 | | |
| (162) Siemens (Atellica) | | 3,37 | 0,085 | 2,5 | 14 | 0 | | | | | | | | | | | | | | | | 14 | | |
| Ostatní | | | | | 10 | 0 | | | | | | | | | | | | | | | | 10 | | |
| | | | | | | | | | | | | | | | | 1x 12, 1x 85, 2x 115, 1x 149, 2x 177, 3x 179 | | | | | | | | |
| **Vzorek B** | | 1,9 | 0,082 | 4,3 | 120 | | | | | | | | 0 | | | CRV | 1,976 | 0,046 | 18% | 1,62 | 2,34 | 120 | 120 | 100 |
| (1) Abbott | | 1,86 | 0,1 | 5,6 | 24 | 0 | | | | | | | | | | | | | | | | 24 | | |
| (46) Erba Lachema | | 2,01 | 0,11 | 5,5 | 5 | 0 | | | | | | | | | | | | | | | | 5 | | |
| (58) Beckman Coulter (AU) | | 1,88 | 0,081 | 4,3 | 19 | 0 | | | | | | | | | | | | | | | | 19 | | |
| (60) Roche | | 1,9 | 0,07 | 3,7 | 48 | 0 | | | | | | | | | | | | | | | | 48 | | |
| (162) Siemens (Atellica) | | 1,92 | 0,05 | 2,6 | 14 | 0 | | | | | | | | | | | | | | | | 14 | | |
| Ostatní | | | | | 10 | 0 | | | | | | | | | | | | | | | | 10 | | |
| | | | | | | | | | | | | | | | | 1x 12, 1x 85, 2x 115, 1x 149, 2x 177, 3x 179 | | | | | | | | |
| (29) **Lipáza** | [µkat/L] | | | | 91 | | | | | | | | 79 | 77 | 97 | | | | | | | 0 | | |
| **Vzorek A** | | 1,01 | 0,069 | 6,8 | 91 | | | | | | | | 79 | 79 | 100 | | | | | | | 0 | | |
| (1) Abbott | | 1,04 | 0,05 | 4,7 | 16 | 0 | CVPG | 1,04 | 0,03 | 24% | 0,79 | 1,29 | 16 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 0,994 | 0,042 | 4,3 | 16 | 0 | CVPG | 0,994 | 0,026 | 24% | 0,755 | 1,24 | 16 | | | | | | | | | | | |
| (60) Roche | | 0,979 | 0,044 | 4,5 | 35 | 0 | CVPG | 0,979 | 0,018 | 24% | 0,744 | 1,22 | 35 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 1,09 | 0,032 | 3 | 12 | 0 | CVPG | 1,09 | 0,023 | 24% | 0,828 | 1,36 | 12 | | | | | | | | | | | |
| Ostatní | | | | | 12 | 0 | | | | | | | 0 | | | | | | | | | | | |
| | | | | | | | 1x 12, 1x 46, 2x 49, 1x 116, 2x 149, 1x 177, 2x 178, 2x 179 | | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 0,507 | 0,034 | 6,7 | 91 | | | | | | | | 79 | 77 | 97 | | | | | | | 0 | | |
| (1) Abbott | | 0,519 | 0,023 | 4,4 | 16 | 0 | CVPG | 0,519 | 0,014 | 24% | 0,394 | 0,644 | 16 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 0,465 | 0,038 | 8,1 | 16 | 0 | CVPG | 0,465 | 0,023 | 24% | 0,353 | 0,577 | 16 | | | | | | | | | | | |
| (60) Roche | | 0,505 | 0,022 | 4,3 | 35 | 0 | CVPG | 0,505 | 0,009 | 24% | 0,383 | 0,627 | 35 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 0,544 | 0,021 | 3,8 | 12 | 0 | CVPG | 0,544 | 0,015 | 24% | 0,413 | 0,675 | 12 | | | | | | | | | | | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS3/24 - Analyty krevního séra

Stop termín: 26.7.2024

Nastavení: skupiny - R (výrobce reagencií); minimální četnost skupin n = 5

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Návaznost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ostatní | | | | | 12 | 0 | | | | | | | 0 | | | | | | | | | | | |
| | | | | | | | 1x 12, 1x 46, 2x 49, 1x 116, 2x 149, 1x 177, 2x 178, 2x 179 | | | | | | | | | | | | | | | | | |
| (8) **Lithium** | [mmol/L] | | | | 24 | | | | | | | | 24 | 21 | 88 | | | | | | | 0 | | |
| **Vzorek A** | | 0,848 | 0,043 | 5 | 24 | | CRV | 0,857 | 0,013 | 12% | 0,754 | 0,96 | 24 | 23 | 96 | | | | | | | 0 | | |
| (60) Roche | | 0,848 | 0,041 | 4,8 | 7 | 0 | | | | | | | 7 | | | | | | | | | | | |
| Ostatní | | | | | 17 | 0 | | | | | | | 17 | | | | | | | | | | | |
| | | | | | | | 1x 0, 3x 1, 1x 11, 1x 19, 1x 46, 2x 58, 1x 61, 1x 77, 1x 116, 4x 162, 1x 179 | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 0,65 | 0,042 | 6,5 | 24 | | CVP | 0,65 | 0,021 | 12% | 0,572 | 0,728 | 24 | 21 | 88 | | | | | | | 0 | | |
| (60) Roche | | 0,639 | 0,057 | 8,9 | 7 | 0 | | | | | | | 7 | | | | | | | | | | | |
| Ostatní | | | | | 17 | 0 | | | | | | | 17 | | | | | | | | | | | |
| | | | | | | | 1x 0, 3x 1, 1x 11, 1x 19, 1x 46, 2x 58, 1x 61, 1x 77, 1x 116, 4x 162, 1x 179 | | | | | | | | | | | | | | | | |
| (18) **Močovina** | [mmol/L] | | | | 152 | | | | | | | | 0 | | | | | | | | | 152 | 148 | 97 |
| **Vzorek A** | | 12,7 | 0,46 | 3,6 | 152 | | | | | | | | 0 | | | CRV | 12,97 | 0,13 | 15% | 11 | 15 | 152 | 151 | 99 |
| (1) Abbott | | 12,8 | 0,55 | 4,3 | 33 | 0 | | | | | | | | | | | | | | | | 33 | | |
| (46) Erba Lachema | | 12,9 | 0,82 | 6,3 | 6 | 0 | | | | | | | | | | | | | | | | 6 | | |
| (58) Beckman Coulter (AU) | | 12,7 | 0,41 | 3,2 | 22 | 0 | | | | | | | | | | | | | | | | 22 | | |
| (60) Roche | | 12,6 | 0,38 | 3 | 62 | 0 | | | | | | | | | | | | | | | | 62 | | |
| (162) Siemens (Atellica) | | 13 | 0,32 | 2,5 | 18 | 0 | | | | | | | | | | | | | | | | 18 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | | | | | | | | | | 11 | | |
| | | | | | | | | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 3x 179 | | | | | | | | |
| **Vzorek B** | | 5,02 | 0,25 | 5 | 152 | | | | | | | | 0 | | | CRV | 5,035 | 0,05 | 15% | 4,27 | 5,8 | 152 | 148 | 97 |
| (1) Abbott | | 5,09 | 0,39 | 7,6 | 33 | 0 | | | | | | | | | | | | | | | | 33 | | |
| (46) Erba Lachema | | 5,02 | 0,24 | 4,9 | 6 | 0 | | | | | | | | | | | | | | | | 6 | | |
| (58) Beckman Coulter (AU) | | 5 | 0,19 | 3,8 | 22 | 0 | | | | | | | | | | | | | | | | 22 | | |
| (60) Roche | | 4,92 | 0,14 | 2,9 | 62 | 0 | | | | | | | | | | | | | | | | 62 | | |
| (162) Siemens (Atellica) | | 5,23 | 0,21 | 4,1 | 18 | 0 | | | | | | | | | | | | | | | | 18 | | |
| Ostatní | | | | | 11 | 0 | | | | | | | | | | | | | | | | 11 | | |
| | | | | | | | | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 3x 179 | | | | | | | | |
| (11) **Osmolalita** | [mmol/kg] | | | | 51 | | | | | | | | 51 | 50 | 98 | | | | | | | 0 | | |
| **Vzorek A** | | 304 | 5,9 | 1,9 | 51 | | CVP | 304 | 2 | 5% | 288 | 320 | 51 | 50 | 98 | | | | | | | 0 | | |
| (119) Advanced Instruments | | 305 | 5,1 | 1,7 | 23 | 0 | | | | | | | 23 | | | | | | | | | | | |
| (150) Arkray | | 300 | 5,6 | 1,9 | 14 | 0 | | | | | | | 14 | | | | | | | | | | | |
| (151) Fiske Associates | | 306 | 0,74 | 0,24 | 6 | 0 | | | | | | | 6 | | | | | | | | | | | |
| (212) GONOTEC GmbH | | 309 | 3 | 0,96 | 6 | 0 | | | | | | | 6 | | | | | | | | | | | |
| Ostatní | | | | | 2 | 0 | | | | | | | 2 | | | | | | | | | | | |
| | | | | | | | 2x 77 | | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 239 | 3,7 | 1,5 | 51 | | CVP | 239 | 1,3 | 5% | 227 | 251 | 51 | 51 | 100 | | | | | | | 0 | | |
| (119) Advanced Instruments | | 239 | 3,1 | 1,3 | 23 | 0 | | | | | | | 23 | | | | | | | | | | | |
| (150) Arkray | | 237 | 2,9 | 1,2 | 14 | 0 | | | | | | | 14 | | | | | | | | | | | |
| (151) Fiske Associates | | 241 | 4,4 | 1,8 | 6 | 0 | | | | | | | 6 | | | | | | | | | | | |
| (212) GONOTEC GmbH | | 242 | 1,5 | 0,61 | 6 | 0 | | | | | | | 6 | | | | | | | | | | | |
| Ostatní | | | | | 2 | 0 | | | | | | | 2 | | | | | | | | | | | |
| | | | | | | | 2x 77 | | | | | | | | | | | | | | | | | |
| (1) **Sodný kation** | [mmol/L] | | | | 154 | | | | | | | | 154 | 146 | 95 | | | | | | | 0 | | |
| **Vzorek A** | | 137 | 2,4 | 1,7 | 154 | | CRV | 138,3 | 2,1 | 5% | 131 | 146 | 154 | 150 | 97 | | | | | | | 0 | | |
| (1) Abbott | | 137 | 2,6 | 1,9 | 35 | 0 | | | | | | | 35 | | | | | | | | | | | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS3/24 - Analyty krevního séra

Stop termín: 26.7.2024

Nastavení: skupiny - R (výrobce reagencií); minimální četnost skupin n = 5

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Návaznost AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (58) Beckman Coulter (AU) | | 136 | 1,8 | 1,3 | 22 | 0 | | | | | | 22 | | | | | | | | | | |
| (60) Roche | | 138 | 1,4 | 1 | 63 | 0 | | | | | | 63 | | | | | | | | | | |
| (162) Siemens (Atellica) | | 139 | 2,3 | 1,7 | 18 | 0 | | | | | | 18 | | | | | | | | | | |
| (179) Siemens | | 141 | 0,44 | 0,32 | 5 | 0 | | | | | | 5 | | | | | | | | | | |
| Ostatní | | | | | 11 | 0 | | | | | | 11 | | | | | | | | | | |
| | | | | | | | 1x 11, 1x 12, 2x 46, 1x 75, 1x 77, 2x 149, 3x 177 | | | | | | | | | | | | | | | |
| **Vzorek B** | | 113 | 2,3 | 2,1 | 154 | | CVP | 113 | 0,46 | 4% | 108 | 118 | 154 | 147 | 95 | | | | | | 0 | | |
| (1) Abbott | | 112 | 1,4 | 1,2 | 35 | 0 | | | | | | 35 | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 112 | 1,7 | 1,5 | 22 | 0 | | | | | | 22 | | | | | | | | | | |
| (60) Roche | | 113 | 1,7 | 1,5 | 63 | 0 | | | | | | 63 | | | | | | | | | | |
| (162) Siemens (Atellica) | | 117 | 1,3 | 1,1 | 18 | 0 | | | | | | 18 | | | | | | | | | | |
| (179) Siemens | | 115 | 0,82 | 0,71 | 5 | 0 | | | | | | 5 | | | | | | | | | | |
| Ostatní | | | | | 11 | 0 | | | | | | 11 | | | | | | | | | | |
| | | | | | | | 1x 11, 1x 12, 2x 46, 1x 75, 1x 77, 2x 149, 3x 177 | | | | | | | | | | | | | | | |
| (20) **Triacylglyceroly** | [mmol/L] | | | | 146 | | | | | | | 0 | | | | | | | | 146 | 145 | 99 |
| **Vzorek A** | | 2,1 | 0,068 | 3,3 | 146 | | | | | | | 0 | | | CRV | 2,104 | 0,021 | 18% | 1,72 | 2,49 | 146 | 145 | 99 |
| (1) Abbott | | 2,03 | 0,037 | 1,8 | 32 | 0 | | | | | | | | | | | | | | | 32 | | |
| (46) Erba Lachema | | 2,12 | 0,025 | 1,2 | 10 | 0 | | | | | | | | | | | | | | | 10 | | |
| (58) Beckman Coulter (AU) | | 2,07 | 0,057 | 2,8 | 21 | 0 | | | | | | | | | | | | | | | 21 | | |
| (60) Roche | | 2,14 | 0,05 | 2,3 | 56 | 0 | | | | | | | | | | | | | | | 56 | | |
| (162) Siemens (Atellica) | | 2,11 | 0,045 | 2,2 | 14 | 0 | | | | | | | | | | | | | | | 14 | | |
| Ostatní | | | | | 13 | 0 | | | | | | | | | | | | | | | 13 | | |
| | | | | | | | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 1x 178, 4x 179 | | | | | | | | |
| **Vzorek B** | | 1,07 | 0,076 | 7,1 | 146 | | | | | | | 0 | | | CRV | 1,023 | 0,013 | 18% | 0,838 | 1,21 | 146 | 145 | 99 |
| (1) Abbott | | 0,979 | 0,025 | 2,6 | 32 | 0 | | | | | | | | | | | | | | | 32 | | |
| (46) Erba Lachema | | 1,12 | 0,026 | 2,3 | 10 | 0 | | | | | | | | | | | | | | | 10 | | |
| (58) Beckman Coulter (AU) | | 1,03 | 0,028 | 2,7 | 21 | 0 | | | | | | | | | | | | | | | 21 | | |
| (60) Roche | | 1,12 | 0,027 | 2,4 | 56 | 0 | | | | | | | | | | | | | | | 56 | | |
| (162) Siemens (Atellica) | | 1,13 | 0,039 | 3,5 | 14 | 0 | | | | | | | | | | | | | | | 14 | | |
| Ostatní | | | | | 13 | 0 | | | | | | | | | | | | | | | 13 | | |
| | | | | | | | | | | | | | | | 1x 12, 1x 85, 2x 149, 4x 177, 1x 178, 4x 179 | | | | | | | | |
| (4) **Vápník celkový** | [mmol/L] | | | | 145 | | | | | | | 145 | 140 | 97 | | | | | | | 0 | | |
| **Vzorek A** | | 2,1 | 0,055 | 2,6 | 145 | | CRV | 2,076 | 0,031 | 8% | 1,9 | 2,25 | 145 | 142 | 98 | | | | | | 0 | | |
| (1) Abbott | | 2,06 | 0,057 | 2,8 | 32 | 0 | | | | | | | 32 | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 2,12 | 0,056 | 2,6 | 21 | 0 | | | | | | | 21 | | | | | | | | | | |
| (60) Roche | | 2,09 | 0,048 | 2,3 | 57 | 0 | | | | | | | 57 | | | | | | | | | | |
| (162) Siemens (Atellica) | | 2,14 | 0,043 | 2 | 17 | 0 | | | | | | | 17 | | | | | | | | | | |
| (179) Siemens | | 2,1 | 0,022 | 1,1 | 5 | 0 | | | | | | | 5 | | | | | | | | | | |
| Ostatní | | | | | 13 | 0 | | | | | | | 13 | | | | | | | | | | |
| | | | | | | | 2x 12, 4x 46, 1x 85, 2x 149, 4x 177 | | | | | | | | | | | | | | | |
| **Vzorek B** | | 1,95 | 0,048 | 2,5 | 145 | | CVP | 1,95 | 0,01 | 7% | 1,81 | 2,09 | 145 | 141 | 97 | | | | | | 0 | | |
| (1) Abbott | | 1,92 | 0,037 | 1,9 | 32 | 0 | | | | | | | 32 | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 1,95 | 0,054 | 2,8 | 21 | 0 | | | | | | | 21 | | | | | | | | | | |
| (60) Roche | | 1,96 | 0,043 | 2,2 | 57 | 0 | | | | | | | 57 | | | | | | | | | | |
| (162) Siemens (Atellica) | | 1,99 | 0,037 | 1,8 | 17 | 0 | | | | | | | 17 | | | | | | | | | | |
| (179) Siemens | | 1,91 | 0,03 | 1,6 | 5 | 0 | | | | | | | 5 | | | | | | | | | | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS3/24 - Analyty krevního séra

Stop termín: 26.7.2024

Nastavení: skupiny - R (výrobce reagencií); minimální četnost skupin n = 5

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Návaznost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ostatní | | | | | 13 | 0 | | | | | | | 13 | | | | | | | | | | | |
| | | | | | | | 2x 12, 4x 46, 1x 85, 2x 149, 4x 177 | | | | | | | | | | | | | | | | | |
| (36) **Vápník ionizovaný** | [mmol/L] | | | | 30 | | | | | | | | 30 | 29 | 97 | | | | | | | 0 | | |
| **Vzorek A** | | 1,35 | 0,037 | 2,7 | 30 | | CVP | 1,35 | 0,017 | 10% | 1,21 | 1,49 | 30 | 30 | 100 | | | | | | | 0 | | |
| (60) Roche | | 1,35 | 0,019 | 1,4 | 9 | 0 | | | | | | | 9 | | | | | | | | | | | |
| (61) Radiometer | | 1,36 | 0,038 | 2,8 | 17 | 0 | | | | | | | 17 | | | | | | | | | | | |
| Ostatní | | | | | 4 | 0 | | | | | | | 4 | | | | | | | | | | | |
| | | | | | | | 1x 38, 1x 46, 2x 179 | | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 1,39 | 0,042 | 3 | 30 | | CVP | 1,39 | 0,019 | 10% | 1,25 | 1,53 | 30 | 29 | 97 | | | | | | | 0 | | |
| (60) Roche | | 1,39 | 0,032 | 2,3 | 9 | 0 | | | | | | | 9 | | | | | | | | | | | |
| (61) Radiometer | | 1,41 | 0,037 | 2,6 | 17 | 0 | | | | | | | 17 | | | | | | | | | | | |
| Ostatní | | | | | 4 | 0 | | | | | | | 4 | | | | | | | | | | | |
| | | | | | | | 1x 38, 1x 46, 2x 179 | | | | | | | | | | | | | | | | | |
| (6) **Železo celkové** | [µmol/L] | | | | 129 | | | | | | | | 129 | 126 | 98 | | | | | | | 0 | | |
| **Vzorek A** | | 23,8 | 0,84 | 3,5 | 129 | | CVP | 23,8 | 0,18 | 15% | 20,2 | 27,4 | 129 | 127 | 98 | | | | | | | 0 | | |
| (1) Abbott | | 24,6 | 0,69 | 2,8 | 31 | 0 | | | | | | | 31 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 23,3 | 0,51 | 2,2 | 20 | 0 | | | | | | | 20 | | | | | | | | | | | |
| (60) Roche | | 23,8 | 0,62 | 2,6 | 51 | 0 | | | | | | | 51 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 23,3 | 0,55 | 2,3 | 13 | 0 | | | | | | | 13 | | | | | | | | | | | |
| (179) Siemens | | 23,7 | 0,23 | 0,97 | 5 | 0 | | | | | | | 5 | | | | | | | | | | | |
| Ostatní | | | | | 9 | 1 | | | | | | | 9 | | | | | | | | | | | |
| | | | | | | | 1x 12, 2x 46, 1x 85, 1x 116, 2x 149, 2x 177 | | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 19 | 0,67 | 3,5 | 129 | | CVP | 19 | 0,14 | 15% | 16,1 | 21,9 | 129 | 127 | 98 | | | | | | | 0 | | |
| (1) Abbott | | 19,5 | 0,64 | 3,3 | 31 | 0 | | | | | | | 31 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 18,6 | 0,42 | 2,3 | 20 | 0 | | | | | | | 20 | | | | | | | | | | | |
| (60) Roche | | 19,1 | 0,56 | 3 | 51 | 0 | | | | | | | 51 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 18,6 | 0,48 | 2,6 | 13 | 0 | | | | | | | 13 | | | | | | | | | | | |
| (179) Siemens | | 18,9 | 0,015 | 0,08 | 5 | 0 | | | | | | | 5 | | | | | | | | | | | |
| Ostatní | | | | | 9 | 0 | | | | | | | 9 | | | | | | | | | | | |
| | | | | | | | 1x 12, 2x 46, 1x 85, 1x 116, 2x 149, 2x 177 | | | | | | | | | | | | | | | | | |